Introduction
Isolated systolic hypertension (ISH) is the most common form of hypertension in the elderly, 1 present in nearly two-thirds of hypertensive individuals over age 60 years, 2 and increasing linearly with age up to about the ninth decade of life. 3 Elevated systolic blood pressure (SBP) is risk factor for cardiovascular and renal disease. 4 Large-scale studies in elderly patients with ISH have documented that treatment of hypertension can be well tolerated and effective in reducing blood pressure (BP) as well as in reducing risk for stroke, 5 cardiovascular events, 6 and overall morbidity and mortality. 7, 8 Thus, effective control of ISH in the elderly is an important medical and public health issue as the aging population increases worldwide.
Angiotensin-II receptor blockers (ARBs) have gained prominence as antihypertensive therapies, particularly in view of their potential benefit in reducing cardiovascular and renal morbidities. Among the ARBs, eprosartan mesylate (Teveten s , Biovail Pharmaceuticals, Inc.) is an orally active, highly selective nonpeptide that has low potential for drug interactions because of its lack of metabolism by cytochrome P450 enzymes, 9 a property that may contribute to the minimization of drug interactions and potentially attractive in the treatment of elderly patients who are often on multiple drug regimens.
Initial experience with eprosartan in the elderly has shown that the drug can be effective and well tolerated in these patients (provided that they are not volume-and/or salt-depleted). In a sub-group analysis of a 26-week, double-blind study, eprosartan at doses of 200-300 mg twice daily alone or in combination with hydrochlorothiazide (HCTZ) 12-25 mg once daily was shown to be safe and effective in hypertensive patients over 65 years of age. 10 In elderly hypertensive patients with predominantly systolic hypertension, eprosartan and enalapril have been shown to be equally effective in reducing sitting SBP (SitSBP) and sitting diastolic BP (SitDBP), with eprosartan reducing the tendency for dry cough seen with the angiotensin-converting enzyme (ACE) inhibitor.
11 Doses up to 800 mg once daily were well tolerated in that study. In spite of such data, there is legitimate concern that in the difficult to treat elder patient, ARBs may not be considered as first-line therapy. Since prior data in adults have shown that eprosartan administered as a once-daily dose is as effective and safe as a twicedaily dose up to 800 mg/day, 12 this study was undertaken to evaluate the efficacy and safety of eprosartan at doses of 600 or 1200 mg administered as a once-daily dose in the treatment of ISH in elderly patients.
Patients and methods

Study design
This was a double-blind, randomized, placebocontrolled, 43-center, international trial in which eprosartan was titrated to effect and compared with placebo for its ability to improve ISH either as monotherapy or as combination therapy with HCTZ.
The study consisted of an initial screening visit, a 3-to 5-week placebo run-in period, and a 13-week double-blind period during which patients were randomized by a computer-generated code in a 1:1 ratio to receive either eprosartan or placebo. A final follow-up visit was scheduled within 5-7 days after the last study dose (Figure 1 ). The 13-week double-blind phase consisted of a 6-week titration phase, a 3-week monotherapy maintenance phase, and a 4-week combination therapy phase. During the titration phase, patients initially received eprosartan 600 mg or matched placebo once daily. Patients who did not respond to the 600 mg dose were titrated up to eprosartan 1200 mg once daily. Vital signs were measured at 2-and 3-h postdose. Titration was followed by a 3-week (monotherapy) maintenance phase. Mean SitSBP was evaluated at weeks 3, 6, and 9. Response to treatment was defined as follows: (a) if mean SitSBP at baseline was 160-175 mmHg, response was defined as a mean decrease of X15 mmHg; (b) if mean SitSBP at baseline was X176 mmHg, response was defined as decrease in a SitSBP to o160 mmHg. At week 9, patients who did not respond to placebo or eprosartan monotherapy (mean SitSBP X145 mmHg and a mean SitDBP X75 mmHg) were given an additional 4-week single-blind diuretic treatment of HCTZ 12.5 mg once daily (combination therapy). Patients who responded to eprosartan monotherapy (mean SitSBP of o145 mmHg and a mean SitDBP o75 mmHg) were considered to have completed the study at week 9 and did not enter the combination-therapy phase. 
Study population
Men or women X60 years of age with ISH (mean SitSBP X160 mmHg and mean SitDBP o90 mmHg at three consecutive run-in visits, with the difference between the highest and lowest SitSBP of p10 mmHg) were included in the study. Patients with malignant hypertension or history of malignant hypertension, secondary forms of hypertension, or mean SitSBP X220 mmHg were excluded from the study as were those with advanced hypertensive retinopathy, significant ventricular tachyarrhythmias requiring therapy, myocardial infarction or cerebrovascular accident within 90 days prior to start of study, congestive heart failure treated with ACE inhibitors or diuretics, untreated reduced ejection fraction, unstable diabetes, or clinically significant renal, hepatic, or other concurrent disease were also excluded from the study. Active alcohol or drug abuse, use of concomitant medications affecting BP, or concomitant chronic treatment with sympathomimetic amines, nonsteroidal anti-inflammatory drugs (except low-dose aspirin 160 mg/day), or monoamine oxidase inhibitors were other exclusion criteria. All qualified patients signed informed consent prior to study entry.
Study medication and treatment
Eprosartan and placebo tablets were matched for appearance and administered each morning. Patients who took o80% or 4120% of medication during intervals between three consecutive visits were considered noncompliant.
Efficacy and safety assessment
The primary measure of efficacy was the mean change from baseline in trough SitSBP at the end of monotherapy, which was defined as the last available SitSBP (using the last observation carried forward (LOCF) method) during the double-blind treatment phase prior to the addition of HCTZ. Secondary efficacy parameters included the mean change from baseline in trough SitSBP at combination-therapy end point; mean change from baseline in standing SBP (StaSBP) at monotherapy and combination-therapy end point; mean change in SitSBP and StaSBP from monotherapy to combination-therapy end point; and placebo-corrected trough-to-peak ratio of SitSBP at end of monotherapy. All patients who received a dose of study medication were monitored for adverse events, fasting clinical laboratory tests, 12-lead electrocardiographic evaluation, and vital signs. All BP measurements were made using a sphygmomanometer. At each centre, manometers were calibrated at annual inspections.
Statistical evaluation
All patients who received at least one dose of study medication were included in the intent-to-treat population and used in all analyses. For BP measurements, comparisons were made by analysis of variance (ANOVA). Differences in least square means of BPs between groups were considered significant if Po0.05. The Cochran-Mantel-Haenzel test was used to evaluate the association between treatment response rates after adjusting for treatment centre differences. Subgroup analyses included assessment of the effects of age (o75, X75 years), gender (female, male), and race (black, white, oriental, other) as covariates in the reduction of SitSBP. A post hoc analysis of pulse pressure was also completed.
Results
Study population and demographics
Of 437 patients screened for eligibility, 283 patients (n ¼ 148, eprosartan; n ¼ 135, placebo) were randomized to receive double-blind treatment with eprosartan or placebo and received at least one dose of study medication (ITT population). For the 154 patients withdrawn prior to randomization, reasons for withdrawal included adverse experience (n ¼ 12), ineligibility based on inclusion/exclusion criteria (n ¼ 87), loss to follow-up (n ¼ 6), protocol violation (n ¼ 6), and other reasons (n ¼ 43). Among randomized patients, 12/148 (8.1%) in the eprosartan group and 21/135 (15.6%) patients in the placebo group withdrew early from the study. The most common reason for early withdrawal was adverse experience. Overall, 98.2% of the ITT population completed monotherapy and 60.8% of subjects entered the combination therapy phase. At end point, 97.8% patients who entered combination therapy in the placebo group and 97.6% patients who entered combination therapy in the eprosartan group remained in the study. Demographic and baseline characteristics were similar in the eprosartan and placebo groups ( Table 1) . The majority of patients were female, white, and o75 years of age. Mean SitSBP at baseline was comparable in the placebo (17070.8 mmHg) and eprosartan (17170.8 mmHg) groups.
Efficacy results
Effect of eprosartan on SitSBP
At the end of monotherapy, trough SitSBP was reduced from 170.6 þ 0.8 at baseline to 152.671.2 mmHg in the eprosartan group and from 170.070.7 to 160.471.6 mmHg in the placebo group. The least squares mean difference between treatments was À7.7 mmHg (95% CI, À10.9, À4.5; Po0.0001). The reduction in trough SitSBP was greater with eprosartan than with placebo at week 3 and persisted at weeks 6 and 9 of monotherapy ( Figure 2) . Following correction for baseline and placebo effects, the mean trough-to-peak ratio for SitSBP was 1.035 at the end of monotherapy (1.05 and 1.02 at peak hours 2 and 3, respectively). Among patients who did not respond to eprosartan monotherapy, the combination of HCTZ and eprosartan was more effective in reducing trough SitSBP than HCTZ alone (Figure 2) . The least-squares mean difference between treatments was À7.4 mmHg (95% CI, À12.0, À2.8; P ¼ 0.0018). Overall, 57.4% of patients treated with eprosartan alone responded to treatment. In contrast, 32% of patients in the placebo group responded (Po0.0001).
Effect of eprosartan on StaSBP
Eprosartan monotherapy was more effective than placebo in reducing trough StaSBP (Table 2a) . The least squares mean difference between treatments was -7.2 mmHg (95% CI, À10.8, À3.7; Po0.0001) (Table 2a) . Among patients who did not respond to eprosartan monotherapy, combination therapy with HCTZ and eprosartan was more effective in reducing mean trough StaSBP than HCTZ alone. The least-squares mean difference between treatments was À5.0 (95% CI, À9.6, À0.4; P ¼ 0.0320) ( Table 2b ).
Effect of eprosartan on trough SitDBP and trough heart rate
No clinically meaningful effects of eprosartan treatment were noted in trough SitDBP or heart rate at monotherapy or combination therapy end points.
Subgroup analyses: effects of age, gender, and race
Subgroup analyses did not reveal any effect of age (o75 vs X75 years), gender, or race on treatment related reduction in SitSBP. However, white patients appeared to respond somewhat better to eprosartan treatment than did black patients (SitSBP reduction 8.9 vs 4.5 mmHg in black vs white patients). No differences in response were found between other races and whites.
Post hoc analysis: effect on pulse pressure
For both eprosartan and placebo groups, maximum reductions in SitDBP occurred at week 13, at the end of combination therapy (À3.3 þ 0.8 vs Reported by X5% of patients in either group. Eprosartan in elderly patients with ISH HA Punzi and CF Punzi -1.370.7 mmHg, respectively); neither group demonstrated reductions 44.0 mmHg from baseline at either the end of monotherapy or combination therapy. There were no differences in pulse pressure between the eprosartan and placebo groups at baseline. At the end of monotherapy, pulse pressure was decreased by 9.1 mmHg in the placebo group and by 16.9 mmHg in the eprosartan group. At the end of combination therapy, pulse pressure decreased by 15.3 mmHg in the placebo group and 17.2 mmHg in the eprosartan group.
Safety results
All 283 patients who were randomized and received at least one dose of study medication were included in safety assessment. The mean duration of therapy for patients taking eprosartan was 77.6 days (range, 5-106 days). Treatment with eprosartan was found to be safe and well tolerated. Of the 148 patients who received eprosartan, 61 (41.2%) experienced at least one on-therapy adverse experience (AE) compared with 66 of 135 (48.9%) of the placebo-treated patients. The frequency of specific on-therapy AE was similar in the two groups. No dose-, age-, gender-, or race-related differences were noted in the incidence of AEs. Overall, 11.3% of patients were considered to have had AEs probably or suspected to be related to their treatment. Most AEs were mild to moderate in nature. The frequency of AEs was 8.2% in the eprosartan group and 14.8% in the placebo group. Dizziness (2% E vs 2.2% P) and asthenia (1.4% E vs 1% P) were the most frequently reported AEs. Severe AEs were experienced in 7/148 (4.7%) eprosartan-treated patients and 10/135 (7.4%) placebo-treated patients. Of these, AEs were considered to be treatment-related in only four patients, three in the placebo group and one in the eprosartan 1200 mg group. Hypertension reported severe AE in the latter patient. Overall, 11/283 (3.9%) patients withdrew from the study due to AEs. Of these, only two had received eprosartan and in both the AE was not considered to be related to eprosartan treatment. There were no deaths during or within 30 days of the study.
Discussion
In this study, we have shown that eprosartan doses up to 1200 mg/day can be well tolerated in elderly patients with ISH and can be effective in lowering SBP. In a majority of patients who began treatment with a SitSBP of 160-175 mmHg in this study, eprosartan alone could decrease trough SitSBP by at least 15 mmHg as per our definition of response. For those with severe hypertension and who began therapy at trough SitSBP X176 mmHg, eprosartan 600 or 1200 mg QD could reduce SitSBP to o160 mmHg. In those who did not respond to eprosartan monotherapy, the addition of a diuretic to the ARB was able to reduce BP. Changes in StaSBP paralleled those of SitSBP, with considerable reductions after monotherapy as well as combination therapy. These data are consistent with previously published data for eprosartan and eprosartan plus HCTZ in the general hypertensive population [11] [12] [13] [14] [15] and extend the efficacy and safety demonstration to eprosartan doses up to 1200 mg/ day either alone or in combination with the diuretic among older (460 years) patients. That trough to peak ratios of SBP were consistently near one at week 9 suggest that the once-daily dosing of eprosartan provides constant reduction of BP throughout the 24-h dosing period in these patients. Further, the BP effects of eprosartan appear not to be influenced by age (o75 vs X75 years), gender, or race although whites responded better than blacks. Finally, eprosartan alone or in combination with HCTZ appears to be well tolerated in the elderly at doses of 600 and 1200 mg/day. While the recent Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT) concluded that the thiazide-type diuretics should be the drug of choice for first-step antihypertensive therapy, 16 controversy surrounds the interpretation and conclusion of the study. This is because the ALLHAT conclusions were based on low cost and efficacy in reducing secondary end points rather than efficacy of diuretics in reducing the primary end point, viz, coronary heart disease, which was found to be identical in patients treated with chlorthalidone, lisinopril, and amlodipine. 17 Data also indicated that most patients require more than one agent for adequate BP control and that diuretics should generally be part of a combination therapy regimen. Additionally, it was found that the diuretic arm of the study had a 40% greater incidence of new onset of diabetes when compared to the ACE Inhibitor. 16 In the present study, we have shown than eprosartan alone or in combination with a diuretic can be effective in reducing SBP in elderly patients with ISH. While a cost analysis is beyond the purview of this manuscript, the lack of persistent cough (as seen with ACE inhibitors), 18 lack of drug interaction, 19 and once-a-day dosing, are additional benefits of eprosartan use. For patients who do not respond to eprosartan alone, the simple addition of a diuretic may be additive and suffice to decrease SBP levels.
